INDIANAPOLIS (dpa-AFX) - Drug major Eli Lilly and Co. (LLY) announced
Tuesday that its pivotal Phase 3 VIVID-1 study of mirikizumab in Crohn's disease
showed that more than one-half of patients achieved clinical remission at one
year, including patients with previous biologic failure.

Crohn's disease is a chronic, inflammatory bowel disease associated with
progressive bowel damage, disability and decreased health-related quality of
life.

In the trial, patients with moderately to severely active Crohn's disease, with
or without previous biologic failure, achieved statistically significant and
clinically meaningful improvements across multiple clinical and endoscopic
endpoints at one year with mirikizumab compared to placebo.

Data from the study, which is the first Phase 3 treat-through data reported for
an IL23p19 antibody, will be presented at Digestive Disease Week, held in
Washington, D.C. from May 18-21.

As previously reported, mirikizumab achieved both co-primary endpoints and all
major secondary endpoints at Week 52 compared to placebo.

The company noted that the overall safety profile of mirikizumab in patients
with moderately to severely active Crohn's disease was consistent with the known
safety profile in patients with ulcerative colitis.

Mark Genovese, senior vice president of Lilly Immunology development, saidd,
'After one year of treatment, more than one-half of patients treated with
mirikizumab achieved clinical remission and nearly one-half achieved endoscopic
response. Remarkably, the majority of patients who achieved either of these
endpoints, achieved both together.'

For More Such Health News, visit rttnews.com



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX